Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborator: GlaxoSmithKline
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Lapatinib; Paclitaxel

Criteria

Inclusion Criteria:

• Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma patients.

• Stage IV metastatic breast cancer patients who have failed no more than four previous chemotherapies for Stage IV disease.

• Ability to swallow and retain oral medications.

• Measurable disease

Exclusion Criteria:

• Treatment with previous weekly carboplatin and paclitaxel.

• No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and cetuximab.

• No concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.